ClinicalTrials.gg
Active, not recruitingNCT04595006Updated Nov 10, 2026

Brown Fat Activation and Browning Efficiency Augmented by Chronic Cold and Nutraceuticals for Brown Adipose Tissue-mediated Effect Against Metabolic Syndrome (BEACON BEAMS Study)

An interventional study of Cold Stimulation (CS) and Browning Nutraceutical (BN) in Energy Expenditure, Obesity and Brown Adipose Tissue, sponsored by Institute for Human Development and Potential (IHDP), Singapore. Active, not recruiting at 1 site in Singapore. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Institute for Human Development and Potential (IHDP), Singapore · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.

Planned enrollment
39th of 68
60 · median 70
Started
2021
with 4 others
No phase
44 of 83
9 open now
Primary completion
2023-10
later than 0 of 24 live
Registered
41st of 83
by date

Among the 83 studies in Obesity with a site in Singapore, this one is the 39th largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2021, is one of 44 with no phase, reaches primary completion later than 0 of the 24 other live ones, and was the 41st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 21 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Obesity with a site in Singapore, or all of them as a file.
02

Study summary

Our body fat (adipose tissue) is largely made up of white adipose tissue (WAT) that stores surplus energy as white fat depots. In addition, adult humans have another type of fat similar to the brown fat in babies that burns up fat to generate heat for maintenance of body temperature during cold exposure. Adults have much lesser amounts of such brown adipose tissue (BAT), most of which are located within the sides of the neck and under the skin above the collar bones as well as along the sides of the spine. BAT consists of both classical brown fat identical to that found in babies as well as beige fat (composed of brown-in-white or 'brite' fat cells) found mainly in adults. Both types of BAT burn fat upon activation by various stimuli such as cold or by substances like curcumin found in turmeric ginger rhizome root.

This study is carried out to find out the effects of cold stimulation and/or a known BAT-activating nutraceutical among those overweight/obese people suffering from metabolic syndrome.

Read the detailed description

This study will recruit 60 participants that are overweight/obese people suffering from metabolic syndrome. The participants will be asked to come to the Clinical Nutrition Research Centre (CNRC) for a screening session (1st visit) and given plenty of time to read this information sheet and the opportunity to ask questions. Once the participants are fully informed regarding the study and all their questions have been satisfactorily answered, the participants will be given a consent form to complete and sign in the presence of the researcher. Following this, in order to gauge their suitability for taking part in the study, an assessment will be carried out. This assessment needs to be carried out in a fasted state and participants would therefore have to come one morning following an overnight fast. The screening will include anthropometric measurements, blood pressure measurement and blood sampling. Anthropometric measurements taken will be height, weight, waist circumference and hip circumference. Body composition will be measured using an electrical impedance analyser (BIA). Blood pressure will be measured using an automatic blood pressure monitor. The participants will also undergo a blood sampling from their vein (6 mL or approximately 1.5 teaspoons) to be tested for thyroid function, glucose and lipid profile. Pre-menopausal females will also undergo a urine pregnancy test to exclude pregnancy prior to participation at study entry. The participants who have been accepted into the study will be randomly assigned to one of the 3 parallel intervention groups below (20 subjects per group) via an online randomizer (www.randomizer.org). Randomization means assigning them to one of the three groups by chance, like tossing a coin or rolling a dice. The 3 parallel intervention groups (Week 0 to 12) are Group 1 (CS): Cold stimulation using cooling vest x 60 min once daily over 3 months, Group 2 (BN): Browning nutraceutical (2000mg curcumin) to be taken once daily over 3 months, Group 3 (CSBN): Cold stimulation using cooling vest x 60 min once daily and Browning nutraceutical (2000mg curcumin) to be taken once daily over 3 months. The participants will then be expected to come to the centre for a total of six separate test sessions, over a span of 6 months (2 test sessions each at week 0, 12 and 24 approximately +/-2 weeks). For each of the six test sessions,the participants will be required to fast overnight and avoid caffeine and alcohol for 8-10 hours, only plain water can be consumed during the fast before reporting at the CNRC in the morning between 8 to 9 am. The participants are to avoid any physical activity/exercise and alcohol on the day prior to the visit. The test sessions will be as follows: On the 2nd visit (first test session) at week 0, the participants will need come to CNRC in the morning and a fasting blood sample (40 mL or approximately 8 teaspoons) and urine sample will be collected before they undergo metabolic rate measurement with IRT focusing on their neck and area above the collar bone in a whole body room calorimeter for the next 45 minutes. The participants will then undergo a mild cold stimulation of about 14 degree Celsius by wearing a cooling vest for the next 45 minutes, in which metabolic rate measurement and IRT in the whole body calorimeter will be performed during this period. Please note that wearing the cooling vest may lead to some shivering, but it is generally considered safe. Upon exiting the whole body calorimeter, the participants will remove the cooling vest and then proceed to Clinical Imaging Research Centre (CIRC) located at the basement level of the same building, where an intravenous indwelling cannula will be inserted into an arm vein and 20 mL (approximately 4 teaspoons) of blood and another urine sample will be collected again. The participants will then wear the cooling vest again for approximately another 60 min and in between they will receive an intravenous injection of a radioactive labeled glucose called 18-FDG through the intravenous cannula. The cooling vest will be removed just prior to the start of the PET (Positron Emission Tomography) and MRI/MRS (Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy) that will take place over the next 1 hour to quantify BAT (Brown Adipose Tissue) and abdominal white fat including liver and muscle fat. The participants will also need to undergo a body composition evaluation using dual energy X-ray absorptiometry (DXA) (approximately 20 mins duration) which allows quantification of fat, lean and bone mass. However, the participants will be given the option to do the DXA scan on their next/3rd visit according to their preference. After which, the participants will be free to leave. On the 3rd visit (second test session) at week 0, the participants will need come to CNRC in the morning for an Oral Glucose Tolerance Test (OGTT). Anthropometric measurements taken will be height, weight, waist circumference and hip circumference. Body composition will be measured using an electrical impedance analyser (BIA). Blood pressure will be measured using an automatic blood pressure monitor. A fasting blood sample (4 mL or less than 1 teaspoon) will be collected and participants will then be required to consume a glucose drink (75g of glucose) within 5 minutes. Subsequently after 120 min, another blood sample (4 mL or less than 1 teaspoon) will be collected. During the entire test session, the participants will have to stay rested and in the laboratory. Television and a workspace will be provided for the participants use if required. At the end of 2 hours of testing, for participants who have not undergone for the DXA scan on the 2nd visit, they will then proceed to complete the DXA scan (approximately 20 mins duration). After which, participants will be free to leave.The above 2 test sessions may be scheduled in any order,but to be completed no more than 2 weeks apart. The participants will now start the study intervention procedures as per the intervention group randomly assigned to them for the next 12 weeks or 3 months. Participants who are assigned to group 1 / cold stimulation (CS), will be expected to undergo a mild cold stimulation of about 14 degree Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months. Participants who are assigned to group 2 / browning nutraceutical (BN), will be expected to consume 2000mg of curcumin (in forms of capsules) daily for the next 12 weeks or 3 months. Curcumin is a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root and has been widely known in Asia to have health benefits. Since both substances are commonly consumed among Asians, it is relevant to study their combined chronic clinical effects on BAT. Use of curcumin to stimulate BAT is essentially safe as both are naturally occurring plant derived substances from Curcuma longa rhizome. It is generally recognised as safe for human consumption. The US FDA has approved curcumin as 'Generally Recognised as Safe' (GRAS) status and allows these to be taken as foods ingredients. Participants who are assigned to group 3 / cold stimulation and browning nutraceutical (CSBN), will be expected to undergo a mild cold stimulation of about 14 degree Celsius by wearing a cooling vest for approximately an hour and, consume 2000mg of curcumin (in forms of capsules) daily for the next 12 weeks or 3 months. The participants will then be required to come for the 4th visit (third test session) and 5th visit (fourth test session) at week 12 (after completing the 3 months of intervention), as per follows:

On the 4th visit (third test session) at week 12, participants will repeat the same procedures as per that of the 2nd visit (first test session). For the 5th visit (fourth test session) at week 12, participants will need to come to CNRC in the morning in a fasted state and proceed first to CIRC for a 30 min MRI/ MRS only scan of BAT/WAT to study the fat composition. Subsequent procedures will be same as that of the 3rd visit (second test session). After which, there will be no more intervention and participants will continue with their usual lifestyle and diet for the next 3 months (week 12 to 24).The participants will lastly be required to come for the 6th visit (fifth test session) and 7th visit (sixth test session) at week 24 (6 months from start of study), and repeat the same procedures as per that of the 2nd visit (first test session) and the 3rd visit (second test session) respectively. Notes: *The 2 test sessions each at week 0, 12 and 24 may be scheduled within 4 weeks from each time point. *The following test sessions will be scheduled no more than 4 weeks apart: o First and second test sessions for Week 0 (in any order) o Third and fourth test sessions for Week 12 (in any order) o Fifth and sixth test sessions for Week 24 (in any order)

03

Conditions studied

  • Energy Expenditure
  • Obesity
  • Brown Adipose Tissue

Browse trials for

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • Chinese, Malay or Indian ethnicity
  • Age between 21 to 50 years
  • Able to give
  • (BMI) between 23 to 32 kg/m2
  • Thyroid function test must be within the normal ranges
  • Willing to avail yourself for the whole study and follow study procedures
  • EITHER deemed to have pre-metabolic syndrome when waist circumference is > 90 cm in men or > 80 cm in women, with none or up to one of the following condition:

    • Triglyceride level ≥ 1.7 mmol/L
    • HDL cholesterol ≤ 1.0 mmol/L in men, and ≤ 1.3 mmol/L in women
    • Blood pressure ≥ 130/85 mmHg
    • Fasting blood glucose of ≥ 6.1 mmol/L
  • OR deemed to have metabolic syndrome when three or more of the following conditions are present:

    • Waist circumference > 90 cm in men and > 80 cm in women
    • Triglyceride level ≥ 1.7 mmol/L
    • HDL cholesterol ≤ 1.0 mmol/L in men, and ≤ 1.3 mmol/L in women
    • Blood pressure ≥ 130/85 mmHg
    • Fasting blood glucose of ≥ 6.1 mmol/L

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or contemplating pregnancy (for female subjects)
  • Partake in sports at the competitive and/or endurance levels
  • Have known glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Have major chronic disease such as heart disease or cancer
  • Take insulin or drugs known to affect glucose metabolism
  • Intentionally restrict food intake
  • Have major medical or surgical event requiring hospitalization within the preceding 3 months
  • Have taken antibiotics for 3 months before the study period
  • Are a smoker
  • Are an overnight shift worker
  • Have any known food allergy (eg. anaphylaxis to peanuts)
  • Having active Tuberculosis (TB) or currently receiving treatment for TB
  • Have any known Chronic Infection or known to suffer from or have previously suffered from or is a carrier of Virus (HBV), Virus (HCV), (HIV)
  • Are a member of the research team or their immediate family members. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  • Enrolled in a concurrent research study judged not to be scientifically or medically compatible with the study of the CNRC
  • Have poor veins impeding venous access
  • Have any history of severe vasovagal syncope (blackouts or near faints) following blood draws
  • History of surgery with metallic clips, staples or stents
  • Presence of cardiac pacemaker or other foreign body in any part of the body
  • History of claustrophobia particularly in a MRI scanner
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cold Stimulation (CS)

    Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.

    Other: Cold Stimulation (CS)

  • Experimental
    Browning Nutraceutical (BN)

    Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.

    Other: Browning Nutraceutical (BN)

  • Experimental
    Cold Stimulation and Browning Nutraceutical (CSBN)

    Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.

    Other: Cold Stimulation and Browning Nutraceutical (CSBN)

Interventions

  • OtherCold Stimulation (CS)

    Subject wear cooling vest to stay cool

  • OtherBrowning Nutraceutical (BN)

    Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root

  • OtherCold Stimulation and Browning Nutraceutical (CSBN)

    Subject wear a cooling vest and consume 2000mg of curcumin

06

What researchers measure

Primary outcomes

  1. Change in Brown adipose tissue activation detection by Imaging using 18-FDG-PET/ MRI.

    Time frame: Week 0, 12 and 24 of cold stimulus

  2. Change in Brown adipose tissue activation detection by Imaging using Infrared

    Time frame: Week 0, 12 and 24 of cold stimulus

  3. Change in Energy Expenditure using Whole Body Calorimeter.

    Time frame: Week 0, 12 and 24 of cold stimulus

  4. Change in Brown adipose tissue activation detection by Imaging using 18-FDG-PET/ MRI.

    Time frame: Week 0, 12 and 24 of consumption of Curcumin

  5. Change in Brown adipose tissue activation detection by Imaging using Infrared

    Time frame: Week 0, 12 and 24 of consumption of Curcumin

  6. Change in Energy Expenditure using Whole Body Calorimeter.

    Time frame: Week 0, 12 and 24 of consumption of Curcumin

  7. Change in Brown adipose tissue activation detection by Imaging using 18-FDG-PET/ MRI.

    Time frame: Week 0, 12 and 24 of cold stimulus and consumption of curcumin

  8. Change in Brown adipose tissue activation detection by Imaging using Infrared

    Time frame: Week 0, 12 and 24 of cold stimulus and consumption of curcumin

  9. Change in Energy Expenditure using Whole Body Calorimeter.

    Time frame: Week 0, 12 and 24 of cold stimulus and consumption of curcumin

07

Study locations

1 site
08

References and documents

Publications

  • Sun L, Goh HJ, Bi X, Chan SP, Leow MK. Cold-induced metabolic flexibility explains ethnic disparities among individuals with obesity and insulin resistance. Int J Obes (Lond). 2026 Jun;50(6):1290-1298. doi: 10.1038/s41366-026-02066-7. Epub 2026 Apr 6. PubMed 41942741 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Oct 2023, 33 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 33 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2020
First posted
Oct 20, 2020
StartActual
Jan 15, 2021
Primary completionActual
Oct 31, 2023
CompletionEst.
Aug 16, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04595006
Lead sponsor
Institute for Human Development and Potential (IHDP), Singapore
Collaborators
Duke-NUS Graduate Medical School, Canadian Imaging Research Centre (CIRC), National University of Singapore, Singapore Institute of Food and Biotechnology Innovation, Singapore Bioimaging Consortium (SBIC)
Responsible party
Melvin Leow (Principal Investigator, Institute for Human Development and Potential (IHDP), Singapore) — Principal investigator
First posted
Oct 20, 2020
Start date
Jan 15, 2021
Primary completion
Oct 31, 2023
Completion
Aug 16, 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion